Johnson & Johnson JNJ

$276.22 +3.90 (1.43%)

Valuation

Market cap
655,558,656,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.95
P/E (forward)
24.86
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,861,000
Avg volume
7,213,330
Day's range
$265.55 – $276.41
Shares out
2,407,310,000
Stochastic %K
67%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

focafoca99 Nov 7, 4:05 PM
$JNJ posted strong Phase 3 data for ICOTYDE, with 58% ACR20 response in psoriatic arthritis at week 16. https://www.rapidticker.com/news/jnj-johnson-johnson-announces-icotydeâ-icotrokinra-5950a6
0 replies
Invescent Nov 7, 3:39 PM
$JNJ | Johnson & Johnson announces significant improvements in psoriatic arthritis disease outcomes from its Phase 3 clinical study.
0 replies
Rayvio_News_Filter Nov 7, 3:04 PM
$JNJ 🏥 Johnson & Johnson announced positive Phase 3 results for ICOTYDE (icotrokinra) in biologic-naive adults with active psoriatic arthritis, with 58% achieving ACR20 and 29% achieving ACR50 at Week 16 on once-daily oral IL-23R targeted peptide. Curated for market relevance
0 replies
zioni007 Nov 7, 1:46 PM
$INO Watch $MRNA or $JNJ buy this company out. They may want to put this into there Pipe line before long.
3 replies
CrazyCajun7 Nov 6, 11:01 PM
$SLS who's there $JNJ
2 replies
BioTechHealthX Nov 6, 10:04 PM
$JNJ Johnson & Johnson (NYSE: JNJ) grew quarterly oncology sales 16.4% to $7.6 billion. Explore the cancer medicines powering growth and the earnings complications investors should examine. https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-flexes-its-oncology-muscle-with-16-4-sales-growth/
0 replies
TraderDaKing Nov 6, 7:35 PM
$ELTP $JNJ $PFE The Earning and Conference Call are going to reveal Much of what will come in 2027...... Next Year will be one of the Biggest Events in Medical ever.
0 replies
TraderDaKing Nov 6, 6:36 PM 0 replies